Bold claim: Blood lactate levels could be the deciding factor in how long ALS patients live. But here’s the part that makes people pause: this biomarker might also reshape how we approach treatment and care.
A joint study from the University of Queensland (Australia) and Japan’s Shiga University of Medical Science identifies blood lactate as a key biomarker capable of predicting physical outcomes and prognosis for individuals with ALS, the most common form of motor neuron disease. ALS gradually erodes voluntary muscle control and can impair breathing, making management of weight and overall health crucial.
In the researchers’ words, lactate is more than just a metabolic fuel; it has long been understood to influence motor neuron survival and the body’s ability to meet the metabolic demands of ALS. Put simply, higher lactate levels in an ALS patient’s blood may correlate with better weight maintenance and a more favorable prognosis.
Initial work by Dr. Ryutaro Nakamura at Shiga University, alongside Professor Makoto Urushitani, began with a Japanese patient cohort. The project expanded when Dr. Nakamura joined a laboratory focused on motor neuron disease led by Associate Professor Shyuan Ngo at the Australian Institute for Bioengineering and Nanotechnology and the UQ School of Biomedical Sciences.
Working with UQ’s Associate Professor Frederik Steyn, the team tracked 146 ALS patients across Japan and Australia. They observed that patients with lower blood lactate levels tended to lose weight more quickly within three months, suggesting a link between lactate, weight trajectory, and disease progression.
Dr. Ngo emphasizes that the Australian and Japanese cohorts strengthen the finding: the relationship between lactate levels, weight loss, and ALS prognosis holds across different populations and settings. This cross-border validation hints that the connection is robust, not tied to a single region or group.
Dr. Nakamura envisions practical consequences: using lactate measurements to guide early nutritional interventions for patients at risk of rapid weight loss and to inform the development of new treatments. Since weight loss is a strong predictor of survival in ALS, identifying those with low lactate early could prompt more aggressive nutritional support to improve outcomes.
The study’s results were published in the Annals of Neurology (DOI: 10.1002/ana.78184).
Controversy and questions to consider: some may wonder whether lactate is a direct driver of better outcomes or simply a proxy for other metabolic factors. How should clinicians integrate lactate testing with existing nutritional and medical strategies for ALS? Could interventions that raise blood lactate inadvertently have unintended effects? What are the ethical implications of using a biomarker to prioritize treatments or resources?
What do you think: should lactate monitoring become a standard part of ALS care, and if so, what thresholds or accompanying tests would you want to see to guide treatment decisions? Share your thoughts in the comments.
